GHK-Cu
The copper-binding peptide behind collagen and skin repair
What GHK-Cu is, how the copper complex drives collagen and tissue repair, why the topical and injectable forms are not the same thing, what the research shows, and its 2026 legal status.
The mechanism
A natural repair signal that works by carrying copper where it is needed.
A copper carrier
GHK binds copper tightly, and the copper complex is the active form. The body's own GHK declines with age, which is part of the interest in it.
Builds the matrix
It increases production of collagen, elastin, matrix proteins and growth factors, and attracts repair cells to tissue, the basis for skin and wound studies.
Calms and protects
It has anti-inflammatory and antioxidant effects and supports regulated copper transport, tied to angiogenesis and antioxidant enzymes.
Topical vs injectable
GHK-Cu is really two different stories, with very different evidence and legal status.
Cosmetic, well studied
A recognized cosmetic ingredient with a large base of use and published skin-science literature on collagen, firmness and fine lines. Legally sold in over-the-counter serums.
Status: real evidence, cosmetic use
Research chemical, thin data
A separate, far less studied application with no cosmetic status and much weaker human evidence. Sold only as a research chemical, not for human use.
Status: experimental, unvalidated
GHK-Cu is also the copper peptide in blends like GLOW.
What the research shows
Decades of skin-science work on the topical form, far less on injection.
Reviews of GHK describe its role in tissue remodeling, attracting repair cells and driving collagen and matrix production, the mechanistic backbone of the skin work.
Pickart, J Biomater Sci 2008 (PMID 18644225)
A 2018 review set out GHK-Cu's regenerative and protective actions in light of gene-expression data, consistent with the firmness and fine-line effects reported for topical use.
Pickart & Margolina, Int J Mol Sci 2018 (PMID 29986520)
The systemic, injected use promoted in some peptide circles has thin human evidence. The cosmetic skin record does not prove that injecting it does the same things.
Preclinical and cosmetic evidence base
The full breakdown: GHK-Cu human studies.
How it is dosed
Route changes everything here, both the evidence and the legal footing.
In a serum or cream, once or twice daily. This is the form with the real evidence and cosmetic status.
Subcutaneous, commonly cited in research-community protocols but not validated and far less studied.
Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.
Side effects
Topical use is well tolerated. Injectable use is the less-understood risk.
- Topical: generally well tolerated, with occasional local irritation or redness, especially at higher concentrations.
- Injectable: injection-site reactions, plus the open question of systemic copper from repeated dosing.
- Copper load: a theoretical concern for systemic use, not well studied, and a real caution for copper-metabolism conditions.
- Source quality: research-grade injectable material is not tested for identity, purity or sterility.
Caution: anyone with Wilson's disease or another copper-metabolism disorder should avoid systemic copper peptides and talk to a doctor. For skin goals, the topical form is the studied one.

GHK-Cu's legal status in 2026
Cosmetic ingredient (topical)
As copper tripeptide-1, topical GHK-Cu is a recognized cosmetic ingredient and is legally sold in over-the-counter serums with appearance-related claims.
Research chemical (injectable)
Injectable GHK-Cu is not FDA-approved, not a cosmetic, and sold only as a research chemical for laboratory use, not for human consumption.
Future FDA review
GHK-Cu was not in the October 2026 HHS compounding policy and is slated for a future FDA advisory committee review, with no determination yet.
Updates: FDA peptide status tracker · how to get peptides legally.
What to monitor
There is no blood marker for GHK-Cu, so for skin goals the honest tool is consistent before-and-after observation.
- Standardized photos in the same light, every few weeks, for skin changes
- Product, concentration and how often you applied it
- Skin feel and any irritation, scored simply
The dashboard logs routines and notes over time so you can tell a real change from a good day.

Common question: does injected GHK-Cu sting?
GHK-Cu is the component people most often link to injection stinging, especially in the KLOW blend. Read why a KLOW injection can burn hours later, or browse more community questions.
Frequently asked questions
What is GHK-Cu?
GHK-Cu is the copper-bound form of GHK, a natural tripeptide (glycyl-L-histidyl-L-lysine) first found in human plasma in the 1970s. GHK binds copper tightly, and the copper complex is the biologically active form studied in most research. Its level in the body declines with age, and it is studied mainly for skin, collagen and wound repair.
How does GHK-Cu work?
Its actions are broad rather than single. GHK-Cu attracts repair cells like macrophages, has anti-inflammatory and antioxidant effects, and increases production of collagen, elastin, matrix proteins and growth factors. Its copper-binding structure also helps move copper into and out of cells, which ties into angiogenesis and antioxidant enzyme activity. Together these support its study in skin and tissue remodeling.
Is GHK-Cu FDA-approved or legal?
It depends on the form. Topical GHK-Cu, listed as copper tripeptide-1, is a recognized cosmetic ingredient, and cosmetics with appearance-related claims do not need FDA premarket approval, which is why it is in many over-the-counter serums. Injectable or subcutaneous GHK-Cu is different: it is not FDA-approved, not a cosmetic, and sold only as a research chemical for laboratory use. GHK-Cu was not in the October 2026 HHS compounding policy and is slated for a future FDA advisory review.
What is the typical GHK-Cu dose?
For skin, topical copper tripeptide-1 is typically used at about a 1 to 2 percent concentration in a serum or cream, once or twice daily, and that is where the real evidence sits. The injectable figure of roughly 1 to 2mg per day seen in research-community protocols is unvalidated and far less studied. Treat the injectable use as experimental, and get any medical use from a prescriber.
What does the research actually show?
The strongest, most replicated evidence is topical and cosmetic: studies of copper-peptide creams report improvements in collagen, skin firmness and the appearance of fine lines, and GHK has a well-documented role in tissue repair and gene expression. The injectable, systemic use promoted in some peptide circles has much thinner human evidence, so the skin-science record should not be read as proof that injecting it does the same things.
Is topical GHK-Cu the same as injecting it?
No, and this is the key distinction. The topical cosmetic form has a large base of use and published skin-science literature. Injectable GHK-Cu is a separate, far less studied application with no cosmetic status and no comparable human evidence base. Results from skin creams do not transfer to systemic injection.
Does GHK-Cu add too much copper?
It is a fair question, since the molecule carries copper. At the small amounts used topically this is generally not a concern, but systemic or injected use raises the theoretical issue of copper load, which has not been well studied in that context. Anyone with a copper-metabolism condition such as Wilson's disease should be especially cautious and talk to a doctor.
Track your protocol
Log products, routines and progress photos in one place, and tell a real change from wishful thinking. Free.
Sources
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-988. PMID 18644225
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID 29986520
- FDA cosmetic ingredient status of copper tripeptide-1 (topical) and a future FDA Pharmacy Compounding Advisory Committee review of GHK-Cu (next round expected in 2027). AJMC summary of the 2026 peptide reviews
This content is for informational purposes only and is not medical advice. Topical GHK-Cu (copper tripeptide-1) is a cosmetic ingredient; injectable GHK-Cu is not FDA-approved and is sold as a research chemical, not for human consumption. GHK-Cu was not included in the October 2026 HHS peptide compounding policy. The strongest human evidence is for topical cosmetic use, not systemic injection. Always consult a qualified healthcare provider before considering any peptide protocol.